Search for: "Discovery Benefits, Inc."
Results 801 - 820
of 1,957
Sort by Relevance
|
Sort by Date
23 Jun 2015, 7:26 am
Sony Pictures Entm’t, Inc., Case No. 2:14-cv-09600 (C.D. [read post]
23 Jun 2015, 6:00 am
The Medical Center, Inc. [read post]
22 Jun 2015, 8:48 am
The plaintiff is seeking damages from Karl Storz Endoscopy-America, Inc., Karl Storz Endovision, Inc., and Karl Storz GMBH & Co. [read post]
22 Jun 2015, 8:48 am
The plaintiff is seeking damages from Karl Storz Endoscopy-America, Inc., Karl Storz Endovision, Inc., and Karl Storz GMBH & Co. [read post]
15 Jun 2015, 11:45 am
Barnett Marine, Inc., Fla: Dist. [read post]
11 Jun 2015, 2:47 pm
In re Jefferies Group, Inc. [read post]
8 Jun 2015, 7:24 am
See PaineWebber, Inc. v. [read post]
2 Jun 2015, 6:42 am
McNeil-PPC, Inc.). [read post]
1 Jun 2015, 9:06 am
Bay Area Renaissance Festival of Largo, Inc., Fla: Dist. [read post]
31 May 2015, 10:21 am
UCF ATHLETICS ASSOCIATION, INC., et al., Respondent. [read post]
28 May 2015, 4:00 am
Electronic discovery is not used to test the quality of ERMS’s. [read post]
27 May 2015, 3:41 pm
In addition the need to respond to the defence will increase discovery costs and multiply the issues the jury must resolve. [read post]
27 May 2015, 9:23 am
Sunbelt Rentals, Inc. [read post]
26 May 2015, 7:42 am
Back then we said:The plaintiff is claiming that a drug is defective, not because of anything inherent in the drug itself, but solely because it is less effective (and therefore has a different risk-benefit profile) due to the plaintiff’s peculiar genetic makeup. [read post]
25 May 2015, 4:00 am
Coenen, CPA, CFF, is a forensic accountant and fraud investigator with Sequence Inc. [read post]
22 May 2015, 10:23 am
In Re Activision Blizzard, Inc. [read post]
21 May 2015, 9:00 am
” Under the policy, “Discovery occur[ed] when [St. [read post]
20 May 2015, 7:04 pm
Google, Inc., Case No. 13-cv-04080-BLF, April 1, 2015 (“Svenson”). [read post]
14 May 2015, 9:27 am
In 2006, Workforce sued Urban Services of America, Inc., for breach of contract when Urban allegedly failed to pay for $573,000 in services. [read post]
14 May 2015, 7:28 am
If a treatment is so new that its risks and benefits cannot accurately be assessed, then a warning about its experimental nature is appropriate, but that kind of warning is a small subset of “off-label use” as an FDA regulatory status.Here is the article’s thesis:This Article proposes a fiduciary framework to regulate physician innovation under conditions of endogenous [we think that means “inherent” in this context] uncertainty. [read post]
